Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 8, 2002, Pages 636-642

  Mantadakis, Elpis ^a   Smith, Angela K ^a   Hynan, Linda ^a   Winick, Naomi J ^a   Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

B cell precursor acute lymphoblastic leukemia; Methotrexate; Polyglutamation; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BONE MARROW; CHILD; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROCORTISONE; INJECTIONS, SPINAL; KARYOTYPING; LEUCOVORIN; LEUKEMIA, PRE-B-CELL; LIFE TABLES; LYMPHOCYTES; MALE; METHOTREXATE; POLYGLUTAMIC ACID; PREDNISONE; PROGNOSIS; PTEROYLPOLYGLUTAMIC ACIDS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; VINCRISTINE;

EID: 0036843610     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200211000-00007     Document Type: Conference Paper

References (34)

1. Pui CH, Evans WE. Acute lymphobtastic leukemia. N Engl J Med 1998;339:605-15.
2. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1993;11:839-49.
3. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group report. J Clin Oncol 1993;11:520-6.
4. Harris MB, Shuster JJ, Pullen DJ, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: A Pediatric Oncology Group Study. J Clin Oncol 1998;16:2840-7.
5. Chessells JM, Harrison G, Lilleyman JS, et al. Continuing (maintenance) therapy in lymphoblastic leukaemia: Lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997;98:945-51.
6. Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997;24:S18/30-S18/39.
7. Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Hormone 1989;45:263-335.
8. Rosenblatt DS, Whitehead VM, Vera N, et al. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. Mol Pharmacol 1978;14:1143-7.
9. Witte A, Whitehead VM, Rosenblatt DS, et al. Synthesis of methotrexate polyglutamates by bone marrow cells from patients with leukemia and lymphoma. Dev Pharmacol Ther 1980;1:40-6.
10. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
11. Whitehead VM, Rosenblatt DS, Vuchich MJ, et al. Accumulation of methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 1990;76:44-9.
12. Winick N, Shuster JJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 1996;14:2803-11.
13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
14. Farrow AC, Buchanan GR, Zwiener RJ, et al. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 1997;15:1560-6.
15. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol Classic Papers Curr Comments 2000;5:134-42.
16. Kamen BA, Winick N. Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol 1986;122:339-46.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
19. SPSS [Computer Program]. Version 10.0.7. Chicago: SPSS Inc.; 2000.
20. Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-6.
21. Allegra CJ, Drake JC, Jolivet J, et al. Inhibition of phosphoribosylaminoimidizolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5.
22. Graham ML, Shuster JJ, Kamen BA, et al. Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: A Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 1992;31:217-22.
23. Ito C, Kumagai M, Manabe A, et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: A distinct biologic entity with a marked propensity to undergo apoptosis. Blood 1999;93:315-20.
24. Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: A Pediatric Oncology Group study. Blood 1992;79:3316-24.
25. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990;76:1449-63.
26. Trueworthy R, Shuster J, Look T, et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 1992;10:606-13.
27. Whitehead VM, Vuchich MJ, Lauer SJ, et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) BCP acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 1992;80:1316-23.
28. Schmiegelow K, Schroder H, Gustafsson G, et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol 1995;13:345-51.
29. Schmiegelow K, Ifversen M. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1996;13:433-41.
30. Rots MG, Pieters R, Peters GJ, et al. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2000;109:629-34.
31. Nachman JB, Sather HN, Sensel MG, et al. Post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-71.
32. Wacker P, Winick NJ, Shuster JJ, et al. Lack of significant correlation between plasma methotrexate (MTX), red blood cells (RBC) methotrexate and RBC folate levels with EFS in children with B-precursor ALL. A Pediatric Oncology Group study [abstract 473]. Blood 2001;98:112a.
33. Hum MC, Smith AK, Lark RH, et al. Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro. Pharmacotherapy 1997;17:1260-6.
34. Mantadakis E, Smith AK, Kamen BA. Ratio of methotrexate to folate uptake by lymphoblasts in children with BCP acute lymphoblastic leukemia: A pilot study. J Pediatr Hematol Oncol 2000;22:221-6.